[HTML][HTML] An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study
Y Cheng, L Wu, J Xin, S Ben, S Chen, H Li… - Journal of Translational …, 2024 - Springer
Background Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Y Cheng, L Wu, J Xin, S Ben, S Chen, H Li… - Journal of …, 2024 - europepmc.org
Background Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study
Y Cheng, L Wu, J Xin, S Ben, S Chen… - Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
[HTML][HTML] An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study
Y Cheng, L Wu, J Xin, S Ben… - Journal of …, 2024 - … -medicine.biomedcentral.com
Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity harboring high
genetic risk, but the majority of EOPC patients still substantial opportunity to be early …
genetic risk, but the majority of EOPC patients still substantial opportunity to be early …
[HTML][HTML] An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study
Y Cheng, L Wu, J Xin, S Ben, S Chen, H Li… - Journal of …, 2024 - ncbi.nlm.nih.gov
Background Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Y Cheng, L Wu, J Xin, S Ben, S Chen… - Journal of …, 2024 - search.ebscohost.com
Background: Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Y Cheng, L Wu, J Xin, S Ben, S Chen, H Li… - Journal of …, 2024 - europepmc.org
Background Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
[PDF][PDF] An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study
Y Cheng, L Wu, J Xin, S Ben, S Chen, H Li… - 2024 - … -medicine.biomedcentral.com
Background Early-onset prostate cancer (EOPC,≤ 55 years) has a unique clinical entity
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …
harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to …